辽宁药监局暂停销售4种严重违规广告药品

2012-11-26 佚名 国家食品药品监督管理局

  近期,辽宁省食品药品监管部门在广告监测中发现,标示为乌兰浩特中蒙制药有限公司生产的丹神定喘、内蒙古库伦蒙药厂生产的欣沸三宝、陕西康惠制药股份有限公司生产的参地益肾口服液、哈尔滨同一堂药业有限公司生产的珍芪降糖胶囊等4种药品在广告宣传中存在扩大产品适应证、使用绝对化用语对产品疗效进行不科学的断言和保证等违规行为,误导欺骗消费者,造成了不良影响。   为严厉打击违法违规发布药品广告行为,保障公众

  近期,辽宁省食品药品监管部门在广告监测中发现,标示为乌兰浩特中蒙制药有限公司生产的丹神定喘、内蒙古库伦蒙药厂生产的欣沸三宝、陕西康惠制药股份有限公司生产的参地益肾口服液、哈尔滨同一堂药业有限公司生产的珍芪降糖胶囊等4种药品在广告宣传中存在扩大产品适应证、使用绝对化用语对产品疗效进行不科学的断言和保证等违规行为,误导欺骗消费者,造成了不良影响。

  为严厉打击违法违规发布药品广告行为,保障公众用药安全有效,根据《药品管理法》及《药品广告审查办法》的有关规定,近日,辽宁省食品药品监督管理局发出通知,对上述药品在全省范围内采取了暂停销售措施,要求全省各地食品药品监管部门通知辖区药品经营企业立即将上述药品下架,不得继续销售,同时加强对企业的监督检查,重点检查销售违规广告药品的经营企业,确保暂停销售措施执行到位。

  辽宁省食品药品监督管理局提醒广大消费者,要在药师和医生的指导下购买和使用药品,切勿盲目相信非法广告宣传。



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747689, encodeId=66111e47689a9, content=<a href='/topic/show?id=528294510d4' target=_blank style='color:#2F92EE;'>#违规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94510, encryptionId=528294510d4, topicName=违规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe7b35947177, createdName=zhao4628, createdTime=Wed Mar 06 17:17:00 CST 2013, time=2013-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687244, encodeId=1f3f168e2440d, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Tue Jul 16 18:17:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301536, encodeId=36d9130153678, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Nov 28 01:17:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]
    2013-03-06 zhao4628
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747689, encodeId=66111e47689a9, content=<a href='/topic/show?id=528294510d4' target=_blank style='color:#2F92EE;'>#违规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94510, encryptionId=528294510d4, topicName=违规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe7b35947177, createdName=zhao4628, createdTime=Wed Mar 06 17:17:00 CST 2013, time=2013-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687244, encodeId=1f3f168e2440d, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Tue Jul 16 18:17:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301536, encodeId=36d9130153678, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Nov 28 01:17:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747689, encodeId=66111e47689a9, content=<a href='/topic/show?id=528294510d4' target=_blank style='color:#2F92EE;'>#违规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94510, encryptionId=528294510d4, topicName=违规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe7b35947177, createdName=zhao4628, createdTime=Wed Mar 06 17:17:00 CST 2013, time=2013-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687244, encodeId=1f3f168e2440d, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Tue Jul 16 18:17:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301536, encodeId=36d9130153678, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Nov 28 01:17:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]
    2012-11-28 xuyu